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As healthcare spending continues to rise,1 resource allocation
decisions will need to be based increasingly on information
about prevalence, severity and chronicity of disorders and
cost-effectiveness of interventions. This will require concern about
specific disorders to be based not only on information about
prevalence and mortality, but also on disability.2,3 Despite the fact
that many studies in high-income countries have estimated the
effects of specific disorders on disability,4–6 comparable broad-
based studies are rare in low- and middle-income countries.7
The aims of the current report are to determine whether in both
low- and middle-income and in high-income countries commonly
occurring mental disorders are as seriously disabling as commonly
occurring physical disorders according to respondent self-reports
obtained in the World Health Organization (WHO) World Mental
Health (WMH) Surveys.7,8
Methods
Sample
World Mental Health surveys were carried out in six countries
classified by the World Bank as low- and middle-income
(Colombia, Lebanon, Mexico, Peoples’ Republic of China, South
Africa, Ukraine) and nine as high-income (Belgium, France,
Germany, Italy, Japan, The Netherlands, New Zealand, Spain
and the USA) (see online Table DS1). The total sample size was
73 441, with individual country samples ranging from 2372 (The
Netherlands) to 12 992 (New Zealand). The weighted average
response rate was 70.3%, with country-specific response rates
ranging from 45.9% (France) to 87.7% (Colombia). All surveys
were based on probability household samples representative of
regions (in China, Colombia, Japan, and Mexico) or nationally
representative (other countries).
All interviews were conducted face to face by trained lay inter-
viewers. Each interview had two parts. All respondents completed
Part I, which contained assessments of core mental disorders. All
Part I respondents who met criteria for any core mental disorder
plus a probability subsample of approximately 25% of other Part I
respondents were administered Part II. The latter assessed corre-
lates, service use and disorders of secondary interest. Physical
disorders were assessed in Part II. The Part II data were weighted
to adjust for oversampling of people with mental disorders and for
differential probabilities of selection within households and to
match samples to population socio-demographic distributions.
Standardised interviewer-training procedures, WHO transla-
tion protocols and quality control procedures were applied across
all WMH countries to ensure comparability. These procedures are
described in more detail elsewhere.8 Informed consent was
obtained in all countries. Procedures for obtaining informed
consent and protecting individuals were approved and monitored
for compliance by the Institutional Review Boards of the
organisations coordinating the surveys in each country.
Measures
Physical disorders were assessed with a standard chronic disorders
checklist9 containing ten conditions that include asthma, cancer,
cardiovascular disease (hypertension, other heart disease), dia-
betes, musculoskeletal disorders (arthritis, chronic back/neck
pain), chronic headaches, other chronic pain disorders and stomach
ulcers. Respondents were asked to report whether they had had any
of the symptom-based conditions (e.g. chronic headaches) in the
past 12 months and to say whether a doctor had ever told them
they had any of the silent conditions (e.g. hypertension) and, if
so, whether they had experienced them in the past 12 months.
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Background
Advocates of expanded mental health treatment assert that
mental disorders are as disabling as physical disorders, but
little evidence supports this assertion.
Aims
To establish the disability and treatment of specific mental
and physical disorders in high-income and low- and middle-
income countries.
Method
Community epidemiological surveys were administered in
15 countries through the World Health Organization World
Mental Health (WMH) Survey Initiative.
Results
Respondents in both high-income and low- and
middle-income countries attributed higher disability to mental
disorders than to the commonly occurring physical disorders
included in the surveys. This pattern held for all disorders
and also for treated disorders. Disaggregation showed that
the higher disability of mental than physical disorders was
limited to disability in social and personal role functioning,
whereas disability in productive role functioning was
generally comparable for mental and physical disorders.
Conclusions
Despite often higher disability, mental disorders are under-
treated compared with physical disorders in both high-
income and in low- and middle-income countries.
Declaration of interest
None. Funding detailed in Acknowledgements.
The British Journal of Psychiatry (2008)
192, 368–375. doi: 10.1192/bjp.bp.107.039107
Checklists of this sort yield more complete and accurate
reports about chronic conditions than do open-ended questions.10
Methodological studies have documented moderate to good
concordance between checklist reports and medical records in
high-income countries.11–14 Comparable studies do not exist in
low- and middle-income countries. Self-reports are obviously less
accurate than assessments based on biological tests. Caution is
consequently needed in interpreting the results of studies such
as this one, that use self-report to assess physical conditions.
The implications of this imperfect assessment were evaluated by
replicating analyses only for people being treated for physical
disorders. People being treated are more likely to meet full
diagnostic criteria and to be more severely disabled than people
who complete a self-report and who are not being treated. A
remaining bias is that the conditions included in the checklist
did not include the infectious diseases that are known to be so
burdensome in low- and middle-income countries.
Mental disorders were assessed with version 3.0 of the WHO
Composite International Diagnostic Interview (CIDI),8 a fully
structured lay-administered interview that generates research
diagnoses of commonly occurring DSM–IV mental disorders.15
The ten disorders considered here include anxiety disorders (panic
disorder, generalised anxiety disorder, specific phobia, social
phobia, post-traumatic stress disorder), mood disorders (major
depressive disorder or dysthymia, bipolar disorder) and
impulse-control disorders (intermittent explosive disorder, adult
attention-deficit hyperactivity disorder, oppositional defiant
disorder). Only disorders present in the past 12 months are
considered. Generally good concordance has been found between
CIDI diagnoses of anxiety/mood disorders and masked clinical
assessment.16 Composite International Diagnostic Interview
diagnoses of impulse-control disorders have not been validated.
Treatment for physical disorders was assessed by asking
respondents whether they had seen a medical doctor or other
health professional in the past 12 months for the disorder. For
mental disorders, disorder-specific treatment was assessed by
asking each respondent whether ‘you ever in your life talk(ed)
to a medical doctor or other professional about (the disorder)’
and, if so, whether ‘you receive(d) professional treatment for
(the disorder) at any time in the past 12 months’. Treatment of
mental disorders was also assessed in a series of more general
questions that asked respondents whether they had visited any
type of professional in the past 12 months (types of professionals
available varied across countries) ‘for problems with your
emotions, nerves, or your use of alcohol or drugs’. Self-reports
about treatment have been shown in previous methodological
studies to have generally good concordance with archival health-
care utilisation records,17 although this research has been carried
out exclusively in high-income countries.
Disability was assessed with the Sheehan Disability Scales
(SDS), a widely used self-report measure of condition-specific
disability that, although up until now used only in the assess-
ment of mental disorders, can just as well be used to assess
disability caused by physical disorders. The SDS consists of
four questions, each asking the respondent to rate on a 0–10
scale the extent to which a particular disorder ‘interfered with’
activities in one of four role domains during the month in the
past year when the disorder was most severe. The four domains
are:
(a) ‘your home management, like cleaning, shopping, and taking
care of the (house/apartment)’ (home);
(b) ‘your ability to work’ (work);
(c) ‘your social life’ (social);
(d) ‘your ability to form and maintain close relationships with
other people’ (close relationships).
The 0–10 response options were presented in a visual analogue
format with labels for the response options of ‘None’ (0), ‘Mild’
(1–3), ‘Moderate’ (4–6), ‘Severe’ (7–9) and ‘Very severe’ (10). A
global SDS disability score was also created by assigning each re-
spondent the highest SDS domain score reported across the four
domains.
Previous methodological studies have documented good inter-
nal consistency reliability across the SDS domains,18,19 a result
that we replicated in the WMH data by finding Cronbach’s alpha
(a measure of internal consistency reliability) in the range 0.82–
0.92 across countries. Importantly, reliability was high both in
high-income countries (median 0.86; interquartile range 0.84–
0.88) and low- and middle-income countries (median 0.90;
interquartile range 0.88–0.90). Previous methodological studies
also have documented good discrimination between role function-
ing of cases and controls based on SDS scores in studies of social
phobia,18 panic disorder,19 post-traumatic stress disorder20 and
substance misuse.21 Similar results were found in the WMH
surveys based on responses to a question asked after the SDS
about days out of role: ‘How many days out of 365 in the past year
were you totally unable to work or carry out your normal activities
because of (the illness)?’ We examined the strength of SDS scores
predicting variation in this relatively objective measure of dis-
ability. If the SDS measures genuine disability, we would expect
correlations to be significant and comparable for physical and
mental disorders. This is, in fact, what we found. In high-income
countries, the multiple correlations of the four SDS domain scores
predicting days out of role were 0.55 for mental disorders and 0.50
for physical disorders. The comparable correlations in low- and
middle-income countries were 0.39 for mental disorders and
0.36 for physical disorders (online Table DS1).
It is important to recognise that the SDS scales are condition-
specific. Respondents were asked to rate the interference to role
functioning caused by a particular disorder rather than the inter-
ference caused by all their health problems. This focused approach
to questioning allows SDS scores to be compared across disorders
without adjusting for comorbidity. However, this requires
respondents with multiple health problems to sort out the relative
effects of their various conditions on their overall functioning. An
indication that respondents are able to do this comes from
controlled treatment studies that have documented significant
improvements in SDS measures of condition-specific role
functioning with treatment for generalised anxiety disorder,22
panic disorder23 and major depression.24
Because they are condition-specific, the SDS scales were
administered separately for each of the ten mental disorders con-
sidered in this report. In the case of the physical disorders, which
were only of secondary interest in the WMH surveys, the SDS
scales were administered for only one physical disorder per
respondent. This one disorder was selected randomly from among
all the physical disorders reported by the respondent as being in
existence during the 12 months before interview. This method
of selection underrepresents comorbid physical disorders, which
may be more severe than the pure (non-comorbid) disorders, as
a function of the number of such disorders. In order to correct
this bias, a weight was applied to each case equal to the number
of physical conditions reported by the respondent.
Statistical analysis
A separate observational record was created for each 12-month
physical disorder for which SDS ratings were obtained (i.e. one
for each respondent who reported one or more disorders) as well
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as for each 12-month mental disorder reported by each
respondent. An otherwise average respondent who met criteria
for five 12-month mental disorders and three physical disorders
would consequently be represented by six records that had a
sum of weights of 8.0: one record for each of the five mental
disorders (each with a condition weight of 1.0) and a sixth record
for a randomly selected physical disorder (with a condition weight
of 3.0).
Standard WMH respondent weights were also applied to each
observational record. As noted above, these weights adjusted for
differential sampling of respondents in the Part I sample as a
function of household size and in the Part II sample as a
function of whether or not core disorders were reported in Part
I. These weighted records, which are representative of the con-
ditions in the populations, were pooled across samples for com-
parative analysis. Domain-specific and global SDS means,
proportions rated severe or very severe (henceforth referred to
as severe) and the standard errors of these estimates were then
calculated separately for each condition in each country and in
more aggregated form for all high-income and all low- and
middle-income countries.
Significance tests were used to test the statistical significance of
pair-wide differences in SDS scores across all pairs of conditions.
Within-disorder comparisons were also made to determine
whether disability ratings differ in low- and middle-income v.
high-income countries. Between-disorder comparisons were made
to determine whether disability ratings are systematically different
for physical disorders than mental disorders within countries. All
these analyses were then replicated using only the subsample of
respondents being treated for physical disorders. Finally, all pair-
wise comparisons were repeated on a within-person basis: that
is, by comparing SDS scores for specific pairs of conditions for
the same individual (e.g. a person who had both depression and
cancer who provided separate SDS ratings for these conditions).
All these significance tests were adjusted for the clustering and
weighting of observations.25 Significance was consistently evaluated
at the 0.05 level with two-sided tests.
Results
Self-reported disorder prevalence and treatment
Despite most prevalence estimates of self-reported chronic
physical disorders differing significantly between high-income
and low- and middle-income countries, the broad pattern of
prevalence estimates is quite similar in the two subsamples (Table
1). Chronic back/neck pain, arthritis, chronic headaches and
hypertension are estimated to be the four most common disorders
in both subsamples. Cancer, diabetes and stomach ulcers are
estimated to be among the least common in both subsamples. Five
of the ten physical disorders are estimated to be more prevalent
in high-income countries and the other five more prevalent in
low- and middle-income countries. The percentage of respondents
that reported receiving treatment for the disorders that we
assessed at the time of interview is generally a good deal
higher in high-income than low- and middle-income countries.
The broad rank-ordering of mental disorder prevalence
estimates is also fairly similar across subsamples despite the fact
that, unlike physical disorders, most mental disorders are
estimated to be significantly more prevalent in high-income than
in low- and middle-income countries. Specific phobia, depression
and social phobia are estimated to be the most prevalent disorders
in both subsamples; oppositional defiant disorder and attention-
deficit hyperactivity disorder are estimated to be the least
common. As with physical disorders, the percentage of respondents
that reported receiving treatment for the disorders that we
assessed at the time of interview is consistently higher in
high-income than in low- and middle-income countries.
The physical disorders were more likely to be treated than the
mental disorders. In high-income countries, 64.9% (n=6720) of all
physical disorders were treated v. 23.7% (n=2637) of all mental
disorders. In low- and middle-income countries, 53.2%
(n=2884) of physical disorders v. only 7.7% (n=319) of mental
disorders were being treated. This pattern also holds for severely
disabling disorders, with 77.6% (n=2172) of severe physical
disorders being treated in high-income countries and 64.0%
(n=763) in low- and middle-income countries compared with
35.3% (n=1378) of severe mental disorders in high-income coun-
tries and 11.9% (n=145) in low- and middle-income countries. It
is noteworthy that these results show the mental–physical treat-
ment gap to be considerably higher in low- and middle-income
countries than in high-income countries.
Individual-level disability
The physical disorders with the highest mean SDS global disability
ratings in both subsamples are chronic pain disorders, although
between-disorder variation in disability ratings is much greater
in high-income than low- and middle-income countries (Table
2). Three physical disorders have significantly higher mean SDS
global disability ratings in high-income countries (back/neck pain,
headaches, other chronic pain disorders). Three others have sig-
nificantly higher ratings in low- and middle-income countries
(asthma, diabetes, hypertension). A similar pattern of relative dis-
ability is found for the proportion of participants rated ‘severely’
disabled in the total sample as well as among those being treated
(online Table DS1).
The mental disorders with the highest mean SDS global
disability ratings in both subsamples are bipolar disorder and
depression. The lowest ratings are for specific phobia. Four mental
disorders (bipolar disorder, depression, generalised anxiety dis-
order, post-traumatic stress disorder) have significantly higher
mean global disability ratings in high-income countries. None
has a significantly higher rating in low- and middle-income
countries. A similar pattern of relative disability is found for the
proportion of participants rated ‘severely’ disabled in the total
sample as well as among those being treated (online Table DS1).
The SDS disability ratings for mental disorders are generally
higher than for physical disorders. This is true, using Mann–
Whitney tests, both for mean disability ratings (low- and
middle-income z=3.0, P=0.002; high-income z=3.0, P=0.002)
and proportions rated severely disabled (low- and middle-income
z=2.5, P=0.011; high-income z=2.7, P= 0.007). Of the 100 logically
possible pair-wise disorder-specific mental/physical comparisons,
mean ratings are higher for the mental disorder in 91 comparisons
in high-income countries and 91 in low- and middle-income
countries. Nearly all of these higher mental than physical ratings
are statistically significant at the 0.05 level. Comparable results
are obtained for severe disability ratings and also for both mean
and severe disability ratings when we control for respondent
age, gender and education, and when we focus exclusively on
the subsamples of participants being treated. (Results available
from the author on request.)
Consistently higher mental than physical disability ratings can
also be found in both high-income and low- and middle-income
countries when individual SDS domains are considered instead of
global ratings (Table 3). These differences are much more pro-
nounced for disability in social life and personal relationships than
in work or household management. For example, the proportions
with severe disability in work functioning associated with mental
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disorders in low- and middle-income and high-income countries
(19.4–21.7%, n=673–2135) are only slightly higher than the pro-
portions associated with physical disorders (17.9–18.1%, n=874–
2028). The proportions with severe disability in social functioning
associated with mental disorders (21.8–28.0%, n=775–2758), in
comparison, are dramatically higher than those associated with
physical disorders (10.3–8.9%, n=513–1168). Similar patterns of
mental/physical differences are found when we compare mean
disability ratings rather than the proportions rated as severe and
when we compare both means and proportions rated as severe
among people being treated (see online Table DS1). In addition,
an attenuated version of the same general pattern holds when
we compare people being treated for physical disorders to all
(i.e. being treated or not) mental disorders to address the concern
that the more superficial assessment of physical than mental
disorders might have resulted in the inclusion of a sub-threshold
of individuals with physical disorders who might have low
disability (online Table DS1).
Discussion
Four key findings emerged from the analyses. First, respondents
generally attributed more disability to their mental rather than
physical disorder. Second, the higher disability of mental
compared with physical disorders held as strongly in low- and
middle-income countries as in high-income countries. Third,
the higher aggregate disability of mental than physical disorder
was much more pronounced for disability in social and personal
relationships than in productive (work and housework) roles.
Fourth, the proportion of participants receiving treatment at the
time of interview was much lower for mental than physical dis-
orders in high-income countries and even more so in low- and
middle-income countries both in the total sample and when we
focused exclusively on participants rated as having a severely
disabling disorder. These findings substantially extend the results
of previous studies, none of which documented comparability
in the disabilities associated with such a varied set of physical
and mental disorders, or disaggregated disability into the domains
considered here to detect the greater relative impact of mental v.
physical disorders in social/personal domains compared with
productive role domains.2,4–7
These results are limited by a number of sampling and
measurement problems. With regard to sampling, results could
be influenced by a truncation of the severity spectrum of physical
disorders. For example, persons facing the end stage of a chronic
physical disease might be institutionalised or not willing or able to
participate in an interview to a greater extent than people with
severe mental disorders, leading to under-estimation of the
relative disability of physical compared with mental disorders.
Whether such a difference in sample bias actually exists, though,
is unknown.
Limitations
There were a number of measurement problems in the analysis.
One is that the physical conditions checklist did not include the
infectious diseases that play such an important part in morbidity
in low- and middle-income countries. Our results consequently
can be generalised only to chronic cardiovascular, digestive,
metabolic, musculoskeletal, pain and respiratory conditions.
However, the conditions considered are important sources of
morbidity even in low- and middle-income countries and the
results are consequently relevant to those countries despite the
exclusion of infectious diseases.
Another measurement problem is that the physical disorders
were assessed by a simple self-report rather than by abstracting
medical records or administering medical examinations. Mental
disorders were assessed more comprehensively with a fully
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Table 1 12-month prevalence of disorders and treatment in high-income and low- and middle-income World Mental Health countries
Disorder prevalence Treatment prevalence among participants
High-income Low- and middle-income High-income Low- and middle-income
na % (s.e.) na % (s.e.) nb % (s.e.) nb % (s.e.)
Physical disorders
Arthritis
Asthma
Back/neck pain
Cancer
Chronic pain
Diabetes
Headaches
Heart disease
High blood pressure
Stomach ulcer
4434
2524
5150
903
1791
1108
3363
1168
3382
529
18.1 (0.4)*
10.0 (0.3)*
19.3 (0.4)*
4.0 (0.2)*
6.0 (0.2)*
4.6 (0.2)
10.9 (0.3)*
4.7 (0.2)*
14.0 (0.4)*
1.9 (0.1)*
1627
542
3375
112
1240
564
3260
1063
2033
786
10.0 (0.3)
3.5 (0.2)
22.0 (0.5)
0.6 (0.1)
8.0 (0.3)
3.9 (0.2)
20.8 (0.6)
5.9 (0.2)
13.1 (0.4)
5.2 (0.3)
1127
494
1632
165
472
373
833
310
1194
120
50.9 (1.8)
51.0 (3.7)
64.8 (1.6)*
51.8 (5.2)
71.5 (3.2)*
94.4 (1.2)*
49.7 (1.8)
77.7 (2.9)*
90.2 (1.4)*
67.7 (5.4)
229
122
54
26
217
168
677
171
553
173
46.6 (4.1)
61.4 (5.4)
43.7 (2.3)
59.6 (10.2)
52.4 (4.4)
76.6 (5.7)
49.7 (2.2)
50.9 (5.3)
69.8 (2.7)
60.6 (4.8)
Mental disorders
ADHD
Bipolar disorder
Depression
GAD
IED
ODD
Panic disorder
PTSD
Social phobia
Specific phobia
249
612
2509
1064
391
76
685
962
1621
2643
0.7 (0.1)*
1.4 (0.1)*
5.7 (0.2)
2.4 (0.1)*
1.1 (0.1)
0.2 (0.0)
1.6 (0.1)*
2.3 (0.1)*
4.1 (0.1)*
6.9 (0.2)*
59
174
1360
360
357
34
211
211
419
829
0.2 (0.0)
0.7 (0.1)
5.2 (0.2)
1.4 (0.1)
1.8 (0.1)
0.2 (0.0)
0.7 (0.1)
0.9 (0.1)
1.9 (0.1)
3.4 (0.2)
81
165
737
327
71
24
212
284
342
394
29.9 (3.7)*
29.1 (2.0)*
29.3 (1.1)*
31.6 (1.8)*
16.7 (2.2)*
33.4 (7.5)
33.1 (2.2)*
29.5 (1.9)*
20.8 (1.1)*
13.2 (0.8)*
9
23
107
22
25
2
24
11
37
59
12.8 (4.2)
13.4 (3.4)
8.1 (1.1)
7.2 (1.9)
5.2 (1.1)
13.5 (10.8)
9.4 (2.4)
8.1 (3.2)
9.3 (2.0)
5.5 (0.9)
ADHD, attention-deficit hyperactivity disorder; GAD, generalised anxiety disorder; IED, intermittent explosive disorder; ODD, oppositional defiant disorder; PTSD, post-traumatic
stress disorder.
a. Number of respondents with the disorder.
b. Number of participants receiving treatment.
*P50.05 v. low- and middle-income, w2-test.
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structured lay-administered diagnostic interview. The more
superficial assessment of physical disorders might have led to
the inclusion of more individuals with sub-threshold physical
disorders than those with sub-threshold mental disorders, intro-
ducing an artificial lowering of the estimated disability of
physical disorders, although we addressed this in our analysis
of treated physical conditions. It might also have led to artificial
overlap between the assessments of mental and physical dis-
orders to the extent that core symptoms of some physical
conditions (e.g. headache, unexplained chronic pain) are
markers of underlying mental disorders, although this would
have attenuated physical/mental differences by increasing
overlap between the two classes of disorders. In addition, the
use of a self-report checklist almost certainly led to an under-
estimation of undiagnosed silent physical conditions. As the
latter are likely to be less disabling than symptom-based con-
ditions or diagnosed silent conditions, this bias presumably
led to an artificial increase in the estimated disability of
physical disorders.
Some of the WMH physical disorder prevalence estimates are
lower than those in gold-standard assessments. For example, the
population prevalence of diabetes has been assessed in a number
of community surveys using glucose tolerance tests on blood
samples.26 A meta-analysis of these studies suggests that the
prevalence of diabetes is highest in North America (9.2%) and
Europe (8.4%), lower in India and most of Latin America
(5–8%), and lowest in most of Africa and China (2–5%).27 The
WMH prevalence estimates, 4.6% in high-income countries and
3.9% in low- and middle-income countries, are lower than these
gold-standard estimates, presumably reflecting the fact that the
latter include undiagnosed cases.
In other instances the WMH prevalence estimates are higher
than those in gold-standard assessments. For example, cancer
prevalence data have been assembled from various administrative
databases and registries in a number of countries.28 Meta-analysis
of these data suggest that cancer is more common in high-income
than low- and middle-income countries, with the highest preva-
lence in North American (1.5% of the population aged 15 and
older diagnosed within the past 5 years), followed by Western
Europe (1.2%), Australia and New Zealand (1.1%), Japan
(1.0%), Eastern Europe (0.7%), Latin America and the Caribbean
(0.4%), with a much lower estimated prevalence in the rest of the
world (0.2%). The much higher cancer prevalence estimates in the
WMH data, 4.0% in high-income countries and 0.6% in low- and
middle-income countries, presumably reflect the fact that cancer
survivors who were diagnosed and treated more than 5 years
ago, although not counted in cancer prevalence estimates because
they have the same survival rates as the general population, often
consider themselves still to have cancer and report this in
community surveys.
Based on comparisons such as these with gold-standard assess-
ments, caution is needed in interpreting the WMH prevalence
estimates of physical disorders. However, the fact that the same
general pattern of higher disability among mental disorders
compared with physical disorders held in comparisons of individ-
uals treated for physical disorders argues strongly that the finding
of higher SDS disability associated with mental than with physical
disorders is not due to imprecision in the measurement of physical
disorders.
Another measurement problem involves the fact that disability
was assessed with brief self-report scales rather than clinical evalu-
ations. This might have introduced upward bias in the reported
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Table 2 Disorder-specific global Sheehan Disability Scale ratings in high-income and low- and middle-income World Mental
Health countries
Mean disability ratings Proportion rated as severely disabled
High-income Low- and middle-income High-income Low- and middle-income
na Mean (s.e.) na Mean (s.e.) nb % (s.e.) nb % (s.e.)
Physical disorders
Arthritis 2140 3.5 (0.1) 580 3.8 (0.2) 526 23.3 (1.5) 127 22.8 (3.0)
Asthma 1040 1.9 (0.2)* 228 3.7 (0.4) 119 8.2 (1.4)* 44 26.9 (5.4)
Back/neck pain 2602 4.8 (0.1)* 1379 3.9 (0.1) 912 34.6 (1.5)* 305 22.7 (1.8)
Cancer 285 2.0 (0.3) 42 3.5 (0.7) 60 16.6 (3.2) 8 23.9 (10.3)
Chronic pain 685 5.2 (0.2)* 418 3.8 (0.3) 296 40.9 (3.6)* 109 24.8 (3.8)
Diabetes 408 2.1 (0.4)* 215 3.5 (0.5) 49 13.6 (3.4) 39 23.7 (6.1)
Headaches 1709 5.4 (0.1)* 1440 4.3 (0.2) 751 42.1 (1.9)* 401 28.1 (2.1)
Heart disease 396 3.3 (0.3) 319 3.8 (0.4) 83 26.5 (3.9) 63 27.8 (5.2)
High blood pressure 1365 1.2 (0.1)* 797 3.5 (0.2) 91 5.3 (0.9)* 144 23.8 (2.6)
Stomach ulcer 170 2.9 (0.4) 312 3.3 (0.4) 31 15.3 (3.9) 59 18.3 (3.6)
Mental disorders
ADHD 228 5.4 (0.2) 45 5.1 (0.5) 87 37.6 (3.6) 14 24.3 (7.4)
Bipolar disorder 588 7.4 (0.1)* 158 6.4 (0.3) 419 68.3 (2.6)* 87 52.1 (4.9)
Depression 1536 7.1 (0.1)* 1241 6.3 (0.1) 1028 65.8 (1.6)* 622 52.0 (1.8)
GAD 1002 6.6 (0.1)* 328 5.5 (0.3) 576 56.3 (1.9)* 127 42.0 (4.2)
IED 387 4.9 (0.2) 345 4.4 (0.3) 136 36.3 (2.8) 106 27.8 (3.6)
ODD 67 5.3 (0.5) 32 5.4 (0.6) 29 34.2 (6.0) 12 41.3 (10.3)
Panic disorder 641 5.8 (0.2) 189 5.2 (0.4) 317 48.4 (2.6)* 67 38.8 (4.7)
PTSD 571 6.5 (0.2)* 112 5.6 (0.4) 329 54.8 (2.8)* 53 41.2 (7.3)
Social phobia 1621 5.0 (0.1) 419 5.4 (0.2) 593 35.1 (1.4) 164 41.4 (3.6)
Specific phobia 2643 3.4 (0.1) 829 3.3 (0.1) 537 18.6 (1.1) 144 16.2 (1.6)
ADHD, attention-deficit hyperactivity disorder; GAD, generalised anxiety disorder; IED, intermittent explosive disorder; ODD, oppositional defiant disorder; PTSD, post-traumatic
stress disorder.
a. Number of respondents with valid Sheehan scores for the randomly selected physical disorder or the mental disorder. Note that the numbers for physical disorder are
substantially lower than those in Table 1 because the prevalence estimates in Table 1 were based on all respondents who reported the disorder whereas the Sheehan
scores were obtained only for the subsample of randomly selected physical disorders. The numbers for mental disorders in this table are slightly lower than those in Table 1
because participants with missing values on Sheehan scores were omitted from this table but not Table 1. Skip errors in the Western European surveys led to the number of cases
with missing Sheehan scores being higher than would normally be expected based on t, respondent refusals and interviewer recording errors.
b. Number of participants rated as having a severely disabling disorder.
*P50.05 v. low- and middle-income, w2-test.
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disability caused by mental disorders compared with physical dis-
orders to the extent that people with mental disorders gave overly
pessimistic appraisals of their functioning. This would seem to be
an unlikely interpretation, though, in that the associations of SDS
ratings with reported numbers of days out of role – a more
objective indicator of disability than the SDS ratings – were found
to be equivalent for mental and physical disorders. Furthermore,
within-person comparison, which controlled for individual
differences in perceptions, found similar results.
Another possibility is that the SDS questions might have been
biased in the direction of assessing the disabilities associated with
mental more than physical disorders. This would seem unlikely,
though, as the SDS questions are quite broad and cover all the
main areas of adult role functioning. Another possible limitation
is that the SDS focused on the ‘worst month’ in the past year,
introducing recall error that possibly was more extreme for physi-
cal disorders than mental disorders. In addition, between-disorder
differences in persistence were not taken into consideration, which
means that particular disorders might have been more dominant
in severity ratings than suggested here if they were more persis-
tently severe than others. The aggregate disability estimates should
be interpreted cautiously because of these limitations regarding
the recall period.
A final measurement problem concerning the assessment of
disability relates to our use of a condition-specific measurement
approach. This is an attractive approach from a statistical perspec-
tive, compared with an unconditional measurement approach (i.e.
an approach that simply assesses overall disability without asking
the respondent to make inferences about the conditions that
caused the disability), because it produces condition-specific
estimates directly, avoiding the need to rely on multivariate
equations that adjust for the effects of comorbidity in predicting
overall disability. However, this advantage in analytic simplicity
is achieved by requiring respondents with comorbid conditions
to perform the difficult task of making judgements about the
effects of individual conditions on their functioning. Because of
likely imprecision in these assessments, it would be useful to
replicate the results reported here in multivariate analyses that
evaluate the separate and joint effects of comorbid conditions in
predicting an unconditional measure of disability. Unfortunately,
the statistical methods needed to estimate models of this sort
are very complex,29 making it difficult to carry out such analyses.
Burden of illness and likelihood of treatment
Within the context of these limitations, the results reported here
are consistent with previous comparative burden-of-illness studies
in suggesting that musculoskeletal disorders and major depression
are the disorders with the largest contribution to disability at the
individual level both in high-income and in low- and middle-
income countries. Previous studies have documented this pattern
only for the USA,30–32 although the importance of depression has
also been documented throughout the world in the World Health
Surveys.7 The current report replicates the World Health Surveys
results regarding depression and documents for the first time
the cross-national importance of musculoskeletal disorders. As
noted above, the WMH results also suggest that mental disorders
are especially disabling to personal relationships and social life,
which implies that they are disabling more because they create
psychological barriers rather than physical barriers to functioning.
Among these barriers are limitations in cognitive and motivational
capacities, affect regulation, embarrassment and stigma,33 and a
tendency to amplify physical symptoms34 and associated disability.35
Given this greater disability of mental than physical disorders,
it is disturbing to find that only a minority of people with severe
mental disorders receive treatment and that treatment is substan-
tially more common for comparably severe physical disorders. In
high-income countries, seriously disabling mental disorders are
only about half as likely to be treated as seriously disabling physi-
cal disorders (35.3% v. 77.6%), and only about 20% as likely to be
treated compared with severe physical disorders in low- and
middle-income countries (11.9% v. 64.0%). This low treatment
rate is consistent with the low rate of recognition and treatment
of mental disorders in primary care, especially if comorbid with
physical disorders.36,37 Combined with the burden of disability
that mental disorders produce, the low treatment rates call for
more attention to mental disorders.
Implications of the WMH findings for treatment are not clear
because, even though treatment effectiveness trials document that
common anxiety and mood disorders can often be successfully
treated,38,39 uncertainties exist regarding long-term outcomes.
Another limitation of existing trials is that they focused on
symptoms and did little to assess the effects of treatment on
reducing disability.38,39 In particular, long-term functional
outcomes are important to track because residual disability and
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Table 3 Sheehan Disability Scale global and domain-specific ratings (proportion rated severely disabled) aggregated across
physical (total and treated) and mental (total) disorders in high-income and low- and middle-income World Mental Health countries
Physical disorders Treated physical disorders Mental disorders
na % (s.e.) na % (s.e.) na % (s.e.)
Global
High-income
Low- and middle-income
2918
1299
23.8 (0.7){
245 (1.2){
2172
735
28.6 (1.0){
29.4 (1.6){
4051
1396
41.3 (0.8)*
37.6 (1.3)
Work
High-income
Low- and middle-income
2028
874
18.1 (0.7)
17.9 (1.0)
1546
517
22.4 (1.0){
21.7 (1.4)
2135
673
21.7 (0.7)*
19.4 (0.9)
Home
High-income
Low- and middle-income
2146
881
17.8 (0.6)
16.7 (1.0){
1608
517
21.3 (0.9)*{
19.8 (1.4)
2011
795
19.9 (0.7)
20.5 (1.0){
Social
High-income
Low- and middle-income
1168
513
0.9 (0.4){
10.3 (0.7){
887
324
10.7 (0.6){
13.7 (1.1){
2758
775
28.0 (0.8)*
21.8 (1.0)
Close relationships
High-income
Low- and middle-income
850
495
6.5 (0.4){
9.0 (0.7){
630
305
7.8 (0.6){
11.7 (1.0){
2375
785
24.3 (0.7)*
21.3 (1.1)
a. Number of participants rated as having a severely disabling disorder.
*P50.05 v. low- and middle-income countries, w2-test. {P50.05 v. mental disorders, w2-test.
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recurrence of disability are major problems with chronic mental
disorders.40 Despite this uncertainty about long-term outcomes,
the results reported here argue strongly that, on the basis of
population disease burden associated with disorder-specific
disability, more attention should be given to the treatment of
mental disorders and that this is especially so in low- and
middle-income countries.
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